Breast
This session will provide a global overview of breast radiotherapy indications, approaches and techniques, informed by the latest clinical trials and relevant research. By the completion of the session, attendees should be able to identify which patients are suitable for omission of radiation therapy for early stage breast cancer, what kinds of genomic tests have been explored for risk stratification, and what techniques and dose/fractionation schemes demonstrate appropriate efficacy and toxicity profiles for definitive breast radiotherapy.
Target Audience
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Appropriately identify patients suitable for omission of adjuvant radiation therapy in early-stage breast cancer.
- Utilize hypofractionation techniques, when applicable, in early-stage breast cancer.
- Identify the relative value and limitations of genomic signatures in risk stratification for breast radiotherapy.
Faculty:
A list of all meeting faculty and Individual presenter disclosures can be found on the Schedule of Events page.
Planning Committee:
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee webpage.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.75 Certificate of AttendanceThis activity was designated for 1.75 AMA PRA Category 1 Credit™.